ClinicalTrials.gg
CompletedNCT01415960Updated Mar 3, 2017Results posted

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

A Phase 3 interventional study of Leuprolide acetate 22.5 mg depot, GP-Pharm SA in Prostate Cancer, sponsored by GP-Pharm. Completed at 25 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-03.

Sponsored by GP-Pharm · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
15th of 69
163 · median 77
Started
2011
with 2 others
Phase 3
26 of 70
3 open now
Registered
29th of 70
by date
Lead sponsor
3 of 70
GP-Pharm

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 15th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2011, is one of 26 in phase 3, and was the 29th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Some patients with prostate cancer benefit from androgen deprivation therapy which reduces levels of testosterone. Leuprolide is a synthetic Luteinizing hormone releasing hormone (LHRH) analogue which upon administration can decrease testosterone levels to ≤0.5 ng/mL. Leuprolide Acetate 22.5 mg Depot is a microencapsulated formulation of leuprolide which is released slowly over time and effectively reduces testosterone levels in many patients to ≤0.5 ng/mL for up to three months. In this study Leuprolide acetate 22.5 mg Depot will be administered by intramuscular injection twice over a period of 6 months. The proportion of patients with testosterone ≤0.5 ng/mL evaluated over a period of 168 days.

Read the detailed description

This in an open-label, multicenter, multiple-dose investigation of 2 doses of leuprolide acetate 22.5 mg administered with a 3-month interval to patients with histologically proven carcinoma of prostate who might benefit from medical androgen deprivation therapy. A total of up to 160 male patients will receive their first single intramuscular injection of leuprolide acetate 22.5 mg on Day 0 (after baseline assessment) and then after 3 months (Day 84). The study duration will be 6 months. Thirty(30) patients will be screened per protocol and enrolled at selected centers to form the PK cohort. The PK/PD analysis will be performed using plasma specimens from the first 20 of 30 patients enrolled in the study (and included in the PK/PD cohort). Patients not belonging to the PK cohort will be screened and enrolled per protocol and will follow the same study schedule as those enrolled in the PK portion of the study, except they will provide only sparse PK sampling.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • androgen deprivation therapy.
  • Leuprolide Acetate Depot Formulation
  • Pharmacokinetics
  • testosterone
  • serum luteinizing hormone
  • follicle-stimulating hormone
  • prostate-specific antigen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Main selection criteria:

Patients with documented prostate cancer who might benefit from medical androgen deprivation therapy (i.e., reduction of androgen levels) will be considered for enrollment in the study if they meet the following criteria:

Inclusion criteria

Inclusion Criteria:

  1. Males ≥18 years of age
  2. Patients with histologically documented prostate carcinoma who might benefit from medical androgen deprivation therapy.
  3. of at least 1 year.
  4. performance status of 0, 1, or 2.
  5. Adequate renal function at Screening as defined by serum creatinine ≤1.6 times the (ULN) for the clinical laboratory.
  6. Adequate and stable hepatic function as defined by ≤1.5 times the ULN and transaminases (i.e., , alanine aminotransferase) ≤2.5 times the ULN for the clinical laboratory at Screening.
  7. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the investigator and to comply with the requirements of the entire study.
  8. Following receipt of verbal and written information about the study,the patient must provide signed before any study related activity is carried out.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of , in the opinion of the investigator, taking into account medical history, clinical observations, and symptoms (rationale: to minimize possibility of serious acute flare reactions that would necessitate concomitant administration of other drugs).
  2. Evidence of spinal cord compression, in the opinion of the investigator, taking into account medical history, clinical observations, and symptoms (rationale: see rationale in criterion 1).
  3. Evidence of severe urinary tract obstruction with threatening urinary retention, in the opinion of the investigator, taking into account medical history, clinical observations, and symptoms (rationale: see rationale in criterion 1).
  4. Presence of any tumor in the immediate vicinity that could cause spinal cord compression, in the opinion of the investigator, taking into account medical history and clinical observations (rationale: see rationale in criterion 1).
  5. Excruciating, severe pain from extensive osseous deposits, taking into account medical history, clinical observations, and symptoms (rationale: see rationale in criterion 1).
  6. Testosterone levels \<1.5 ng/mL at Screening, This testosterone level will be locally determined at the laboratory of each clinical site (rationale: to ensure that all patients have normal baseline testosterone levels).
  7. Previous androgen ablative therapy lasting more than 6 months, such as LHRH analogues (e.g., Leuprolide acetate, Goserelin, Buserelin) or antagonists (degarelix). Also, therapy must have not occurred within 12 months before the screening visit. Any prior ADT must have not exceeded 6 months of therapy.
  8. Previous treatment with androgen-receptor blockers, such as Bicalutamide, Flutamide, Megestrol acetate, Ciproterone will only be allowed after a 3 month prior to the screening visit (rationale: these therapies alter a patient's androgenic hormonal response for a sustained period).
  9. Previous orchiectomy, adrenalectomy, or hypophysectomy (no washout allowed) (rationale: these therapies could have altered a patient's androgenic hormonal response).
  10. Previous prostatic surgery (e.g., radical prostatectomy, transurethral resection of the prostate) within 2 weeks before Baseline (rationale: these therapies could have altered a patient's androgenic hormonal response and/or adverse reaction profile).
  11. Previous local therapy to the primary tumor with a curative attempt other than surgery (external beam radiotherapy, brachytherapy, thermotherapy, cryotherapy) within 2 weeks before Baseline (rationale: these therapies could have altered a patient's adverse reaction profile).
  12. Previous cancer systemic therapy such as chemotherapy, immunotherapy (e.g., antibody therapies, tumor vaccines), biological response modifiers (e.g., cytokines).
  13. Any drug within 5 half-lives of its physiological action or 3 months, whichever is longer, before Baseline (rationale: to prevent adverse effects of another drug being attributed to study drug and to prevent potential interactions).
  14. Administration of 5-α-reductase inhibitors (Finasteride, Dutasteride) within 3 months before Baseline (rationale: alters PSA levels and androgen metabolism of the prostate cells). Prior use of 5-α-reductase inhibitors will be allowed with a 3 month washout.
  15. Over-the-counter or alternative medical therapies that have an estrogenic or antiandrogenic effect (i.e., PC-SPES, saw palmetto, Glycyrrhiza, Urinozinc, dehydroepiandrosterone) within the 3 months before Baseline.
  16. Hematological parameters (red blood cells, total and differential white blood cell count, count, , hematocrit) outside 20% of the or lower limits of normal for the clinical laboratory at Screening (rationale: to render potential study drug-related laboratory abnormalities easier to observe).
  17. Coexistent , in the opinion of the investigator (rationale: to decrease possibility of disease-caused or associated therapy-caused adverse effects being attributed to study drug).
  18. Uncontrolled congestive heart failure, myocardial infarction or a coronary vascular procedure (e.g., balloon angioplasty, coronary artery bypass graft) or significant symptomatic cardiovascular disease(s) within 6 months before Baseline; resting uncontrolled hypertension (≥160/100 mm Hg) or symptomatic hypotension within 3 months before Baseline (rationale: to decrease possibility of disease-caused or associated therapy-caused adverse effects being attributed to study drug).
  19. Venous thrombosis within 6 months of Baseline (rationale: influencing testosterone levels may be associated with increased likelihood of deep venous thrombosis).
  20. Uncontrolled diabetes, in the opinion of the investigator (rationale:

    patients with uncontrolled diabetes need to compensate the metabolic disorder before treatment with LHRH analogues).

  21. History of drug and/or alcohol abuse within 6 months of Baseline (rationale: these patients are likely to have numerous medical abnormalities and are unlikely to comply with protocol).
  22. Serious concomitant illness(es) or disease(s) (e.g., hematological, renal, hepatic, respiratory, endocrine, psychiatric) that may interfere with, or put patients at additional risk for, their ability to receive the treatment outlined in the protocol (rationale: to decrease possibility of disease-caused or associated therapy-caused adverse effects being attributed to study drug).
  23. Patients on anticoagulative therapy including warfarin (Coumadin®), Dabigatran Etexilate (Pradaxa®) and heparin. Those patients on low-dose, low-molecular weight heparin may be enrolled in the study (rationale: to decrease possibility of disease-caused or associated therapy-caused adverse effects being attributed to study drug). Plavix and Aspirin are allowed for cardiac prophylaxis as long as all inclusion/exclusion criteria are met concerning coagulation parameters and thromboembolic history. Special care to avoid hematoma at the injection site must be observed.
  24. Abnormal coagulation studies ( [PT]/partial thromboplastin time [PTT]) at Baseline.
  25. History of serious bleeding on injections, an elevated INR, concomitant medications or any other condition (i.e. significant thrombocytopenia) that in opinion of the investigator would render the subject at risk of significant bleeding with injections.
  26. Blood donations/losses within 2 months of Baseline, apart from previous prostatic surgery patients (see exclusion 10 [rationale: to avoid excessive blood donations]).
  27. Known to GnRH, GnRH agonists, including any LHRH analogues, or any of the study formulation (rationale: to minimize hypersensitivity reaction to study drug).
  28. History of Immunization (within 4 weeks of Baseline) and specifically flu shots (within 1 week of Baseline or 1 week before and after study drug administration) (Rationale: to decrease the possibility of non treatment-related AEs being attributed to study drug).
  29. Skin disease that would interfere with injection site evaluation.
  30. Men not willing to use appropriate methods such as surgical sterilization or barrier contraception or men with partners of child bearing potential not willing to use appropriate birth control methods, such as surgical sterilization, hormonal birth control (partner), an intrauterine device (partner) or double-barrier method for the entire study period.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Leuprolide acetate 22.5 mg depot

    Leuprolide acetate 22.5 mg depot administered twice, 3 months apart

    Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.

    The primary endpoint was testosterone ≤ 0.5 ng/mL assessed on Days 28, 84, and 168. Thereby, maintenance of castration was to be demonstrated through Day 168 with no missing data at these key time points, unless the missing data were due to an event unrelated to the study drug (ITT patients).

    Time frame: 168 days

Secondary outcomes

  1. Determination of Serum Luteinizing Hormone (LH)

    For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=2.00). If the calculated mean, median or minimum value at a time point was less than LLOQ, "BLQ" is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.

    Time frame: 168 days

  2. Follicle-stimulating Hormone (FSH)

    For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=3.66). If the calculated mean, median or minimum value at a time point was less than LLOQ, "BLQ" is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was to be calculated for that time point.

    Time frame: 168 days

  3. Prostate-specific Antigen (PSA) Concentrations

    For purposes of calculating summary statistics, any concentration values Below Limit Quantification (BLQ) were to be assigned ½ the Low Limit Quantification (LLOQ) (LLOQ=0.36). If the calculated mean, median or minimum value at a time point was less than LLOQ, "BLQ" is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.

    Time frame: 168 days

  4. Determination of Leuprolide Cmax

    Leuprolide Pharmacokinetic Parameters (PK Population).

    Time frame: Cmax1: 0, 1 and 4 hours post-dose on Day 0 and once on Days 2, 14, 28, 56; Cmax2: 0, 1 and 4 hours post-dose on Day 84 and once on Days 86, 112 and 168.

  5. Safety Endpoints

    The WHO/ECOG, bone pain, urinary pain and urinary symptoms data reported are the most frequent percentage at the assessment time. * The WHO/ECOG performance status was summarized using the 0 to 4 WHO/ECOG performance status scale. (0= fully active, able to carry on all pre-disease performances without restriction). * Bone pain, urinary pain and urinary symptoms were determined using a 10-point scale (1= no pain/symptoms, 10= worst pain/symptom imaginable).

    Time frame: 168 Days

  6. Determination of Leuprolide Tmax

    Leuprolide Pharmacokinetic Parameters (PK Population).

    Time frame: 84 days

07

Results

Posted Jan 18, 2017

Participant flow

Participant flow — Overall Study
MilestoneLeuprolide Acetate 22.5 mg Depot
Started163
Itt161
Pk subgroup30
Completed151
Not completed12

Outcome measures

PrimaryPercentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.

The primary endpoint was testosterone ≤ 0.5 ng/mL assessed on Days 28, 84, and 168. Thereby, maintenance of castration was to be demonstrated through Day 168 with no missing data at these key time points, unless the missing data were due to an event unrelated to the study drug (ITT patients).

Time frame:
168 days
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.
percentage of participantsLeuprolide Acetate 22.5 mg Depot
Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.98.1 (94.7 to 99.6)
SecondaryDetermination of Serum Luteinizing Hormone (LH)

For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=2.00). If the calculated mean, median or minimum value at a time point was less than LLOQ, "BLQ" is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.

Time frame:
168 days
Reported as:
Mean · mIU/mL
Determination of Serum Luteinizing Hormone (LH)
mIU/mLLeuprolide Acetate 22.5 mg Depot
Baseline7.24 ± 6.48
Day 281 ± 2.79
Day 1681 ± 0.92
SecondaryFollicle-stimulating Hormone (FSH)

For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=3.66). If the calculated mean, median or minimum value at a time point was less than LLOQ, "BLQ" is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was to be calculated for that time point.

Time frame:
168 days
Reported as:
Mean · mIU/mL
Follicle-stimulating Hormone (FSH)
mIU/mLLeuprolide Acetate 22.5 mg Depot
Baseline15.14 ± 13.46
Day 281 ± 1.44
Day 1685.80 ± 3.62
SecondaryProstate-specific Antigen (PSA) Concentrations

For purposes of calculating summary statistics, any concentration values Below Limit Quantification (BLQ) were to be assigned ½ the Low Limit Quantification (LLOQ) (LLOQ=0.36). If the calculated mean, median or minimum value at a time point was less than LLOQ, "BLQ" is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.

Time frame:
168 days
Reported as:
Mean · ng/mL
Prostate-specific Antigen (PSA) Concentrations
ng/mLLeuprolide Acetate 22.5 mg Depot
Baseline44.36 ± 165.81
Day 1682.37 ± 10.30
SecondaryDetermination of Leuprolide Cmax

Leuprolide Pharmacokinetic Parameters (PK Population).

Time frame:
Cmax1: 0, 1 and 4 hours post-dose on Day 0 and once on Days 2, 14, 28, 56; Cmax2: 0, 1 and 4 hours post-dose on Day 84 and once on Days 86, 112 and 168.
Reported as:
Mean · ng/mL
Determination of Leuprolide Cmax
ng/mLLeuprolide Acetate 22.5 mg Depot
Day 0/Dose 1 Cmax46.79 ± 18.008
Day 84/Dose 2 Cmax48.30 ± 18.557
SecondarySafety Endpoints

The WHO/ECOG, bone pain, urinary pain and urinary symptoms data reported are the most frequent percentage at the assessment time. * The WHO/ECOG performance status was summarized using the 0 to 4 WHO/ECOG performance status scale. (0= fully active, able to carry on all pre-disease performances without restriction). * Bone pain, urinary pain and urinary symptoms were determined using a 10-point scale (1= no pain/symptoms, 10= worst pain/symptom imaginable).

Time frame:
168 Days
Reported as:
Number · percentage of participants
Safety Endpoints
percentage of participantsLeuprolide Acetate 22.5 mg Depot
Baseline WHO/ECOG Score 0 (n=161)83.9
Day 168 WHO/ECOG Scores 0 (n=152)82.9
Baseline Bone Pain score 1 (n=161)95.0
Day 168 Bone Pain score 1 (n=152)94.1
Baseline Urinary Pain score 1 (n=161)98.8
Day 168 Urinary Pain Score 1 (n=152)97.4
Baseline Urinary Symptoms score 1 (n=161)87.6
Day 168 Urinary Symptoms score 1 (n=152)89.5
SecondaryDetermination of Leuprolide Tmax

Leuprolide Pharmacokinetic Parameters (PK Population).

Time frame:
84 days
Reported as:
Mean · day
Determination of Leuprolide Tmax
dayLeuprolide Acetate 22.5 mg Depot
Day 0/Dose 1 Tmax0.07 ± 0.051
Day 84/Dose 2 Tmax0.08 ± 0.056

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate 22.5 mg Depot—12/163 (7.4%)141/163 (86.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLeuprolide Acetate 22.5 mg Depot
SYNCOPENervous system disorders3/163
CONGESTIVE HEART FAILURECardiac disorders1/163
MYOCARDIAL INFARCTIONCardiac disorders1/163
DIARRHEAGastrointestinal disorders1/163
INCARCERATED INGUINAL HERNIAGastrointestinal disorders1/163
RECTAL BLEEDINGGastrointestinal disorders1/163
NON-CARDIAC CHEST PAINGeneral disorders1/163
PNEUMONIAInfections and infestations1/163
FALLInjury, poisoning and procedural complications1/163
DEHYDRATIONMetabolism and nutrition disorders1/163
Most frequent other events
Most frequent other events
EventLeuprolide Acetate 22.5 mg Depot
TEAE Related Hot FlushesVascular disorders126/163
TEAE Related FatigueGeneral disorders16/163
TEAE Related Injection site painGeneral disorders15/163

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Leuprolide Acetate 22.5 mg Depot
<=18 years0
Between 18 and 65 years42
>=65 years119
Age, Continuous
Age, Continuous(years)Leuprolide Acetate 22.5 mg Depot
Mean71 ± 9.02
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate 22.5 mg Depot
Female0
Male161
Region of Enrollment
Region of Enrollment(participants)Leuprolide Acetate 22.5 mg Depot
United States161
08

Study locations

25 sites
  • Genesis Research
    San Diego, California 92123, United States
  • Atlantic Urological Associates
    Daytona Beach, Florida 32114, United States
  • Urology Health Team
    Ocala, Florida 34474, United States
  • Winter Park Urology Associates, PA
    Orlando, Florida 32803, United States
  • Coastal Medical Center
    Sarasota, Florida 34237, United States
  • North Idaho Urology
    Coeur d'Alene, Idaho 83814, United States
  • Idaho Urologic Institute
    Meridian, Idaho 83642, United States
  • First Urology
    Jeffersonville, Indiana 47130, United States
  • Mid Atlantic Clinical Research
    Greenbelt, Maryland 20770, United States
  • Premier Urology Associates, LLC
    Lawrenceville, New Jersey 08648, United States
  • The Urological Institute of Northeastern New York
    Albany, New York 12208, United States
  • Brooklyn Urology Research Group
    Brooklyn, New York 11215, United States
  • Manhattan Medical Research
    New York, New York 10016, United States
  • The Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • Staten Island Urological Research, PC
    Staten Island, New York 10304, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • PMG Research of Winston Salem
    Winston Salem, North Carolina 27103, United States
  • Urologic Consultants of SE PA
    Bala Cynwyd, Pennsylvania 19004, United States
  • Urology Health Specialists, LLC
    Bryn Mawr, Pennsylvania 19010, United States
  • Greenville Health System
    Greer, South Carolina 29650, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology Associates, PC
    Nashville, Tennessee 37209, United States
  • Urology San Antonio Research, PA
    San Antonio, Texas 78229, United States
  • Urology of Virginia
    Virginia Beach, Virginia 23462, United States
  • Seattle Urology Research Center
    Burien, Washington 98166, United States
09

References and documents

Publications

  • Shore ND, Guerrero S, Sanahuja RM, Gambus G, Parente A. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer. Clin Ther. 2019 Mar;41(3):412-425. doi: 10.1016/j.clinthera.2019.01.004. Epub 2019 Feb 8. PubMed 30929678 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2011
First posted
Aug 12, 2011
Start
Sep 2011
Primary completionActual
May 2013
CompletionActual
Nov 2013
Results first posted
Jan 18, 2017
Last update
Mar 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01415960
Lead sponsor
GP-Pharm
Responsible party
Sponsor
First posted
Aug 12, 2011
Start date
Sep 2011
Primary completion
May 2013
Completion
Nov 2013
Results posted
Jan 18, 2017
Last update
Mar 3, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion